Cofounders: Startup ObjectiveGI is ramping-up ahead of Series B raise
Summary
NASHVILLEs ObjectiveGI Inc. is likely to begin Series B planning this fall and is "just now starting discussions on what the next round will look like in terms of capital raise and potential partners," said Don Lazas MD, the startups chief medical officer and co-founder. At this time, the startup is exclusively focused on forging a network of partnerships that supports patients and providers, as well as pharmaceutical companies efforts to develop candidate therapies and then gain regulatory and market acceptance for those that address nonalcoholic steatohepatitis (NASH). VNC notes, for example, that Intercept Pharma (ICPT), is presenting this week during the JP Morgan Health Care Conference, now underway in San Francisco, and is likely to be questioned by conferees about its OCA candidate. Potential long term partners will emerge as our platform grows and expands to other disease states..." Asked about advisors, Hoke said the company relies on attorneys with Nelson Mullins, while its accounting is with LBMC and it banks with Pinnacle Financial. Hokes career spans about 28 years in related fields with employers including CirQuest Labs, Novum Pharmaceutical Research Services, Charles River Laboratories, and the former Memphis listed company, Response Oncology Inc. She is active in LifeScience Tennessees entrepreneur mentorship program.